Bioimpedance signals recorded from the lower limbs of a patient with early-stage varicose veins before and after massage

Subject
Subject is female, 27 years old, nonsmoker, BMI= 23.1 (kg/m2), there is a genetic susceptibility in the family to the occurrence of varicose veins.
The measurements were made after confirming the varicose in the right leg in the early stages, and the second measurement was made after a five-minute local massage of the leg.
Equipment
The equipment used is the multi-channel electrical impedance research system REO-32. This system has the following characteristics: 30 precordial electrical impedance channels, one transthoracic bioimpedance channel, one ECG channel, channel sampling rate is 500 HZ, bioimpedance measurement method is tetropolar, probe current amplitude is 1 mA, probing frequency is 100 kHz, pulse impedance measurement range is (−2∼+2) Ohm , and bandwidth of the bioimpedance channel is (0.01∼117) Hz.
Channels:
Transthoracic ;
Right thigh (RLU);
Right leg (RL);
Lower part of the right leg (RLD);
Left thigh (LLU);
Left leg (LL);
Lower part of the left leg (LLD);
ECG.
Institutional Review Board Statement: The study that collected the data was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Scientific and educational medical-technological center of Bauman Moscow State Technical University (Institutional Review Board Statement No 1 on 28 January 2021).
Informed Consent Statement: Informed consent was obtained form subject involved in the study.

受试者
受试者为女性，27岁，无吸烟史，身体质量指数（Body Mass Index, BMI）为23.1 kg/m²，家族存在下肢静脉曲张遗传易感性。首次测量于确诊右侧下肢早期静脉曲张后开展，第二次测量则在对腿部实施5分钟局部按摩后完成。

实验设备
本次研究所用设备为多通道生物电阻抗研究系统REO-32。该系统具备以下特性：30个心前区生物电阻抗通道、1个经胸生物电阻抗通道、1个心电图（Electrocardiogram, ECG）通道；通道采样率为500 Hz；生物电阻抗测量采用四极法；探头电流幅值为1 mA；探测频率为100 kHz；脉冲阻抗测量范围为(-2~+2) Ω；生物电阻抗通道带宽为(0.01~117) Hz。

测量通道
本次研究的测量通道包括：经胸通道、右大腿（RLU）、右小腿（RL）、右小腿下段（RLD）、左大腿（LLU）、左小腿（LL）、左小腿下段（LLD）以及心电图通道。

机构伦理委员会声明
本数据采集研究严格遵循《赫尔辛基宣言》指南开展，并已通过鲍曼莫斯科国立技术大学科学与教育医疗技术中心伦理委员会审批（伦理审查编号：第1号，2021年1月28日）。

知情同意声明
本研究已获取所有参与受试者的知情同意。